Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades Amyris to Perform

Oppenheimer Downgrades Amyris to Perform

Oppenheimer analyst Colin Rusch downgrades Amyris (NASDAQ:AMRS) from Outperform to Perform.

byBenzinga Newsdesk

November 9, 2022

1 minute read

Oppenheimer analyst Colin Rusch downgrades Amyris (NASDAQ:AMRS) from Outperform to Perform.

Barclays Maintains Equal-Weight on loanDepot, Lowers Price Target to $1

By Benzinga Newsdesk

October 17, 8:12 AM

Barclays analyst Mark Devries maintains loanDepot (NYSE:LDI) with a Equal-Weight and lowers the price target from $2 to $1.

LDI

What’s Going On With Obesity Drug-Developer Altimmune Inc Stock?

By Erica Kollmann

January 4, 2:08 PM

Altimmune, Inc. (NASDAQ: ALT) shares are trading higher Thursday, and the stock has gained more than 140% over the past month.

ALT

Why This Analyst Is Upgrading Check Point Software, Downgrading These 3 Networking, Security Stocks

By Priya Nigam

July 20, 12:01 PM

Some key networking and security companies are scheduled to report earnings next week. Despite the decline in valuation, some stocks still do not reflect the likely deterioration in financials, according to BofA Securities.

ANET

Baird Maintains Neutral on NVIDIA, Lowers Price Target to $150

By Benzinga Newsdesk

July 14, 10:28 AM

Baird analyst Tristan Gerra maintains NVIDIA (NASDAQ:NVDA) with a Neutral and lowers the price target from $165 to $150.

NVDA

Oppenheimer Downgrades Amyris to Perform

Related Posts

Barclays Maintains Equal-Weight on loanDepot, Lowers Price Target to $1

What’s Going On With Obesity Drug-Developer Altimmune Inc Stock?

Why This Analyst Is Upgrading Check Point Software, Downgrading These 3 Networking, Security Stocks

Baird Maintains Neutral on NVIDIA, Lowers Price Target to $150